二线化疗在敏感复发性小细胞肺癌患者中的疗效。
Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer.
机构信息
Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan
Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
出版信息
In Vivo. 2019 Nov-Dec;33(6):2229-2234. doi: 10.21873/invivo.11727.
Abstract
BACKGROUND/AIM: To evaluate treatment efficacy of cisplatin, etoposide, and irinotecan combined therapy (PEI), platinum-rechallenge chemotherapy (Pt-Re) and amrubicin monotherapy (AMR) for patients with sensitive relapsed small cell lung cancer (SCLC).
PATIENTS AND METHODS
We defined sensitive relapse as treatment-free interval (TFI) ≥90 days. We retrospectively collected patients' data from medical records between September 2002 and December 2016. Patients with sensitive relapsed SCLC who received second-line chemotherapy were separated into those treated with PEI, with Pt-Re, or with AMR.
RESULTS
Seventy-one patients (16 PEI group, 27 Pt-Re group, and 28 AMR group) were assessable for efficacy. No significant differences in patient characteristics were found among the three groups. The median overall survival (MST) was 29.3 months in the PEI group, 24.6 months in the Pt-Re group, and 20.6 months in the AMR group (p=0.042).
CONCLUSION
A significant difference was observed in the overall survival of patients treated with PEI, Pt-Re and AMR and the MST of PEI was the longest.
摘要
背景/目的：评估顺铂、依托泊苷和伊立替康联合治疗（PEI）、铂类药物再挑战化疗（Pt-Re）和氨柔比星单药治疗（AMR）对敏感复发性小细胞肺癌（SCLC）患者的治疗效果。
患者和方法
我们将治疗无进展期（TFI）≥90 天定义为敏感复发。我们回顾性地从 2002 年 9 月至 2016 年 12 月的病历中收集了患者的数据。接受二线化疗的敏感复发性 SCLC 患者分为接受 PEI、Pt-Re 或 AMR 治疗的患者。
结果
71 例患者（16 例 PEI 组、27 例 Pt-Re 组和 28 例 AMR 组）可评估疗效。三组患者的一般特征无显著差异。PEI 组的中位总生存期（MST）为 29.3 个月，Pt-Re 组为 24.6 个月，AMR 组为 20.6 个月（p=0.042）。
结论
PEI、Pt-Re 和 AMR 治疗患者的总生存期存在显著差异，PEI 的 MST 最长。
相似文献
1
Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer.二线化疗在敏感复发性小细胞肺癌患者中的疗效。
In Vivo. 2019 Nov-Dec;33(6):2229-2234. doi: 10.21873/invivo.11727.
2
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.安鲁米星与每周顺铂/依托泊苷/伊立替康治疗复发性小细胞肺癌患者的比较
Clin Lung Cancer. 2017 Mar;18(2):234-240.e2. doi: 10.1016/j.cllc.2016.09.005. Epub 2016 Oct 25.
3
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.敏感复发性小细胞肺癌患者再次化疗的疗效。
Am J Clin Oncol. 2015 Feb;38(1):28-32. doi: 10.1097/COC.0b013e318286907b.
4
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.接受铂类/依托泊苷再挑战治疗的铂敏感小细胞肺癌患者的结局：一项多机构回顾性分析
Clin Lung Cancer. 2015 Nov;16(6):e223-8. doi: 10.1016/j.cllc.2015.04.006. Epub 2015 Apr 24.
5
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.在敏感复发性小细胞肺癌患者中用铂类方案进行再挑战治疗。
Med Oncol. 2018 Apr 2;35(5):61. doi: 10.1007/s12032-018-1123-6.
6
Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.根据广泛期小细胞肺癌先前化疗敏感性的氨柔比星治疗临床结果。
Osaka City Med J. 2011 Dec;57(2):59-66.
7
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.老年患者及体能状态较差患者接受氨柔比星单药治疗后复发的小细胞肺癌铂类化疗的疗效
Oncology. 2018;94(4):207-214. doi: 10.1159/000486038. Epub 2018 Jan 31.
8
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.联合顺铂、依托泊苷和伊立替康化疗与拓扑替康单药二线治疗敏感复发性小细胞肺癌患者（JCOG0605）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14.
9
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.随机 II 期临床试验比较氨柔比星与铂类双联再挑战治疗敏感复发性小细胞肺癌患者：日本北部肺癌研究组试验 0702。
Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4.
10
A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.一项关于氨柔比星单药治疗老年复发性小细胞肺癌的回顾性研究。
Cancer Chemother Pharmacol. 2017 Sep;80(3):615-622. doi: 10.1007/s00280-017-3403-9. Epub 2017 Jul 31.
引用本文的文献
1
The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report.复发性广泛期小细胞肺癌中化疗与免疫检查点抑制剂联合应用：一例报告
J Cardiothorac Surg. 2025 Jul 5;20(1):286. doi: 10.1186/s13019-025-03513-8.
2
Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer.每两周一次的伊立替康是治疗复发或难治性小细胞肺癌的一种有效且便捷的治疗方案。
BMC Cancer. 2024 Oct 1;24(1):1218. doi: 10.1186/s12885-024-12935-x.
3
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).一线含免疫检查点抑制剂治疗后复发小细胞肺癌患者中氨柔比星的临床疗效：一项回顾性多中心研究（TOPGAN 2021-01）。
Thorac Cancer. 2023 Jan;14(2):168-176. doi: 10.1111/1759-7714.14729. Epub 2022 Nov 21.
4
Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study.铂类双联疗法用于小细胞肺癌三线治疗的可行性与安全性：一项多机构回顾性研究
Oncol Lett. 2022 Sep 1;24(4):368. doi: 10.3892/ol.2022.13488. eCollection 2022 Oct.
5
Ageing as key factor for distant metastasis patterns and prognosis in patients with extensive-stage Small Cell Lung Cancer.衰老作为广泛期小细胞肺癌患者远处转移模式和预后的关键因素。
J Cancer. 2021 Jan 15;12(6):1575-1582. doi: 10.7150/jca.49681. eCollection 2021.
6
Evaluation of Hippo Pathway and CD133 in Radiation Resistance in Small-Cell Lung Cancer.评估小细胞肺癌中Hippo信号通路和CD133在辐射抗性中的作用
J Oncol. 2021 Jan 13;2021:8842554. doi: 10.1155/2021/8842554. eCollection 2021.
本文引用的文献
1
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.联合顺铂、依托泊苷和伊立替康化疗与拓扑替康单药二线治疗敏感复发性小细胞肺癌患者（JCOG0605）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14.
2
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.随机 II 期临床试验比较氨柔比星与铂类双联再挑战治疗敏感复发性小细胞肺癌患者：日本北部肺癌研究组试验 0702。
Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4.
3
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.接受铂类/依托泊苷再挑战治疗的铂敏感小细胞肺癌患者的结局：一项多机构回顾性分析
Clin Lung Cancer. 2015 Nov;16(6):e223-8. doi: 10.1016/j.cllc.2015.04.006. Epub 2015 Apr 24.
4
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.随机 III 期试验：氨柔比星对比拓扑替康作为小细胞肺癌二线治疗药物。
J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10.
5
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.敏感与难治性复发性小细胞肺癌标准定义的验证：拓扑替康二线试验的汇总分析
Eur J Cancer. 2014 Sep;50(13):2211-8. doi: 10.1016/j.ejca.2014.06.002. Epub 2014 Jun 26.
6
A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).阿霉素氨丁酸盐治疗难治性小细胞肺癌的单臂确证性研究：日本临床肿瘤学组研究（JCOG0901）。
Lung Cancer. 2014 Apr;84(1):67-72. doi: 10.1016/j.lungcan.2014.01.012. Epub 2014 Jan 25.
7
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.敏感复发性小细胞肺癌患者再次化疗的疗效。
Am J Clin Oncol. 2015 Feb;38(1):28-32. doi: 10.1097/COC.0b013e318286907b.
8
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.二线化疗在敏感和难治性小细胞肺癌中的疗效的系统分析。
J Thorac Oncol. 2012 May;7(5):866-72. doi: 10.1097/JTO.0b013e31824c7f4b.
9
Small-cell lung cancer.小细胞肺癌。
Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10.
10
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.随机 II 期试验：单药氨柔比星或拓扑替康作为一线铂类化疗敏感的小细胞肺癌患者的二线治疗。
J Clin Oncol. 2011 Jan 20;29(3):287-93. doi: 10.1200/JCO.2010.29.8851. Epub 2010 Dec 6.
Zotero 插件